Ryan Kole
Directeur Général chez Beyond Barriers Therapeutics, Inc.
Profil
Ryan Kole is currently the Chief Executive Officer at Beyond Barriers Therapeutics, Inc. and a Partner at Vcapital, Inc. He holds an MBA from The University of Chicago and an undergraduate degree from the University of Illinois at Urbana-Champaign.
Postes actifs de Ryan Kole
| Sociétés | Poste | Début |
|---|---|---|
Vcapital, Inc.
 Vcapital, Inc. Investment ManagersFinance Vcapital Inc (Vcapital) is a venture capital firm founded in 2000 by Len A Batterson and James Vaughan. The firm is headquartered in Chicago, Illinois. | Private Equity Investor | 01/01/2016 |
Beyond Barriers Therapeutics, Inc.
 Beyond Barriers Therapeutics, Inc. BiotechnologyHealth Technology Beyond Barriers Therapeutics, Inc. is an American company that is developing a novel product to treat inflammation and cell death following traumatic brain injury (TBI). The company is based in Illinois, and the CEO of the company is Ryan Kole. The company aims to decrease the harmful effects of TBI by providing active therapy that could be administered intranasally immediately after impact to the head. The company's proprietary technology will lay the foundation for use of a novel, more effective delivery mechanism of small molecules to the brain. | Directeur Général | - |
Formation de Ryan Kole
| The University of Chicago | Masters Business Admin |
| University of Illinois At Urbana–Champaign | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Vcapital, Inc.
Vcapital, Inc. Investment ManagersFinance Vcapital Inc (Vcapital) is a venture capital firm founded in 2000 by Len A Batterson and James Vaughan. The firm is headquartered in Chicago, Illinois. | Finance |
Beyond Barriers Therapeutics, Inc.
Beyond Barriers Therapeutics, Inc. BiotechnologyHealth Technology Beyond Barriers Therapeutics, Inc. is an American company that is developing a novel product to treat inflammation and cell death following traumatic brain injury (TBI). The company is based in Illinois, and the CEO of the company is Ryan Kole. The company aims to decrease the harmful effects of TBI by providing active therapy that could be administered intranasally immediately after impact to the head. The company's proprietary technology will lay the foundation for use of a novel, more effective delivery mechanism of small molecules to the brain. | Health Technology |
